Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pancreatic Cancer Clear all

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Advance Solid Tumors
Interventions: KIVU-107; Drug
Lead sponsor: Kivu Bioscience Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Santa Monica, California • New Have, Connecticut

Conditions: Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions: filgrastim, docetaxel, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions: SS1(dsFv)-PE38 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Bethesda, Maryland • Winston-Salem, North Carolina

Conditions: Malnutrition, Pancreatic Cancer
Interventions: proteolytic enzymes, gemcitabine hydrochloride, Gonzalez regimen; Biological · Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: KRAS G12D Mutation, Advanced Solid Cancer
Interventions: ARV-806; Drug
Lead sponsor: Arvinas Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more

Conditions: Pancreatic Cyst
Interventions: Not listed
Lead sponsor: Translational Genomics Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Newport Beach, California • Atlanta, Georgia

Conditions: Cancer of Liver, Pancreatic Cancer, Biliary Tract Cancer
Interventions: HPB Surgery; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cancer of Pancreas
Interventions: Walking Intervention; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation, Pancreas Cancer, Metastatic, Pancreas Cancer, Recurrent, Pancreas Cancer, Stage IV Pancreatic Cancer, Stage 4 Pancreatic Cancer
Interventions: Melphalan, BCNU, Vitamin B12B, Vitamin C, Autologous Hematopoietic Stem Cells; Drug · Device
Lead sponsor: General Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Advanced Solid Tumors
Interventions: BMS-986466, Adagrasib, Cetuximab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more

Conditions: Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
Interventions: SGN-CD47M; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more

Conditions: Pancreatic Cancer
Interventions: EUS-FNA with Corkscrew technique, Expect 19 G Flex needle; Procedure · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
Interventions: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin; Biological
Lead sponsor: Anza Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: gemcitabine hydrochloride, imatinib mesylate; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 120 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 8
States / cities: Chicago, Illinois • Freehold, New Jersey • Hamilton, New Jersey + 3 more

Conditions: Pancreatic Cancer
Interventions: Biliary stent placement; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pancreas Cancer
Interventions: PREHAB; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer
Interventions: Avutometinib (VS-6766) + Defactinib (VS-6063); Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pancreatic Cancer
Interventions: HyperAcute-Pancreatic Cancer Vaccine; Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pancreatic Cancer
Interventions: High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT); Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Trametinib, Ruxolitinib, Retifanlimab; Drug
Lead sponsor: Peter Hosein, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neuroendocrine Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Peposertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more

Conditions: Pancreatic Cancer
Interventions: TraceIT Tissue Spacer implantation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Houston, Texas

Search by objective public record fields.

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Blood and Cystic Fluid From Patients Undergoing Surgery for Worrisome Pancreatic Cysts

Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery

A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study

Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction

A Supervised Prehabilitation Program for Patients With Pancreatic Cancer

Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma

Vaccine Treatment for Surgically Resected Pancreatic Cancer

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer